Vet Clin Path Journal Fri, 04 Jun 2021 20:31:07 +0000 en-US hourly 1 Vet Clin Path Journal 32 32 TTU Veterinary School receives $ 350,000 gift from Bank of America Fri, 04 Jun 2021 19:32:11 +0000

Texas Tech University School of Veterinary Medicine in Amarillo received a donation of $ 350,000 from Bank of America to build and support a new world-class veterinary school to address the growing shortage of veterinary resources in the region.

The 185,000 square foot two-story facility currently under construction will welcome its first students later this year. When fully implemented, the school is expected to accommodate more than 450 veterinary and graduate students, according to a press release from Texas Tech.

While the veterinary studies program is firmly focused on general veterinary practice in rural and regional communities, the graduate program will produce scientists who will provide solutions to the world’s most pressing problems.

“Our facilities are truly world class,” said Guy Loneragan, Dean of SVM. “They will be a fantastic academic home for our students, staff and faculty. We are so grateful to our community, the region as a whole, and Bank of America for making these facilities and our programs a reality. This donation will help create a premier space for students and support essential programs and recruiting efforts across the region. “

Source link

]]> 0
Medical Student Pledges to Live Meaningful Life by Helping Others | Information Center Fri, 04 Jun 2021 16:09:39 +0000

Study the Harvard / MGH Center on Genomics, Vulnerable Populations, and Health Disparities website and find out what Bobak Seddighzadeh was doing before he began his studies at the Kirk Kerkorian School of Medicine at UNLV.

Bobak Seddighzadeh is an associate researcher at the Harvard / MGH Center of Genomics, Vulnerable Populations and Health Disparities. During his graduate studies at the Gallatin School at New York University, he studied population genetics and medical genetics and graduated as a class valedictorian. Since then, Seddighzadeh has focused his research at the intersection of genomics and health inequalities. Now, as project manager of the Jamaica Institute for Cancer Care and Research (JACCRI), his work includes assisting in the development of a prospective study on the genetics of prostate cancer in Jamaican men and establishing national guidelines on palliative care for the Jamaican Ministry of Health.

Yes, Seddighzadeh, now ready to earn his MD in 2022, already has an impressive resume. His research has been published in peer-reviewed journals, including: Epigenomics, BioMedicine, and European urology. As a member of the charter class of the medical school, he took time between his second and third year of medical school to pursue additional training in cancer genomics in Dr Franklin Huangfrom the University of California at San Francisco, a doctor-researcher whom he met at Harvard.

Fight against vaccine hesitancy

As Seddighzadeh focused in Huang’s cancer lab, at the height of the pandemic, Huang turned his lab’s attention to understanding COVID-19. “At the time, a trend emerged where both men and women contracted COVID at similar rates, but men died in greater proportions than women,” Seddighzadeh said. “We studied publicly available genomic datasets on human lungs to see whether or not there were sex differences between lung cells in males and females that would explain this phenomenon. Indeed, we have found that men have a higher percentage of lung cells that express the receptors that COVID-19 needs to infiltrate our cells. “

Huang and Seddighzadeh also studied the prostate to see if there is any potential for COVID-19 infiltration. “Surprisingly, we found that the prostate also has the pairs of receptors needed for COVID to infiltrate the cell, albeit in very small amounts. “

Seddighzadeh points out that much more research needs to be done before the clinical implications of the research done in Huang’s lab can be revealed. As part of his research, Seddighzadeh, with Huang as a mentor, designed a study to understand the genetic basis of aggressive prostate cancer.

“I am on an authentic journey to learn all I can,” said Seddighzadeh, who received a full scholarship at the Kerkorian School of Medicine in 2017 courtesy of Dr. Barbara Atkinson, Founding Dean, and Maureen Schafer, former team leader of the faculty of medicine. “I want to lead a determined life and for me that means taking the time to pursue meaningful projects that have great potential to help others through medicine.”

Concerned about the reluctance to vaccinate, Seddighzadeh wrote a piece for Men’s health magazine on the Safety of COVID-19 mRNA Vaccines. He also wrote a guest column for the Las Vegas Sun, arguing that the benefits of the Johnson & Johnson vaccine far outweighed the risk of blood clots.

Jamaica Project

A graduate with honors in biology and biochemistry from Loyola Marymount University in California, Seddighzadeh completed two years of research on health disparities at the Charles R Drew / UCLA Medical Education Program before going to New York University (NYU ) for his graduate studies. After graduating from NYU, he received a job offer at Harvard from a renowned researcher he met during his graduate studies, Dr Alexandra E. Shields, director of the Harvard / MGH Center of Genomics, Vulnerable Populations, and Health Disparities. At Harvard Medical School, he helped study how psychosocial stress modulates our stress circuit (also known as the HPA axis) to understand how it can influence chronic disease.

“Dr. Shields had a grand vision to help establish a world-class cancer institute in Kingston, Jamaica,” said Seddighzadeh. “She was inspired by their unusually high cancer rates combined with their dramatic need for research. and clinical ability. I had no doubts in my mind that this was an experience I wanted to be a part of. I wanted to help improve the fight against cancer, learn how to create organizations and start-ups. up, as well as participating in an international experiment. I was hired by Dr Shields to be the Cancer Institute’s first project director and to move to Kingston to help establish the institute from scratch. I maintained my role until my first year of medical school, after which I quit to concentrate on my studies.

The cancer center in Jamaica is now funded by the National Institutes of Health.

“I hope, in one way or another, to help UNLV establish its own world-class cancer center and research institute for the city of Las Vegas,” said Seddighzadeh, who believes the medicine’s future is in “precision medicine”, or the use of one’s genetic makeup to tailor treatments to that person.

Parental influence

Seddighzadeh, who lost his father to pancreatic cancer between his second and third year of medical school, said the experience with Dr. Shields and the cancer center “gave me the confidence to be a leader. in the field of cancer ”.

His parents immigrated to the United States from Iran to give their children better opportunities in life. They moved from California to Las Vegas four years before Seddighzadeh began medical school. “My father and mother were the yin and yang of my development. My father was a serial entrepreneur – very logical, meticulous and hardworking. From him I learned the value of discipline and perseverance. He instilled in me a mindset of growth – that I can accomplish whatever I choose as long as I continue to learn, work hard, and persist despite setbacks. My mother was a clinical psychologist. She transmitted to me the values ​​of ethics, simplicity, benevolence, well-being towards others and generosity. She instilled in me emotional intelligence and awareness. I think it is the unique combination of their skills that has given me a foundation to hopefully make progress as a great physician for my patients and as a leader for my community.

Education has always been emphasized in Seddighzadeh’s family. “In college, I remember I almost made my mom cry when I brought home a ‘B’ because she knew I was capable of more.”

Seddighzadeh’s favorite question growing up was “Why?” “

“I remember when I was 8 years old, I wanted to understand how electricity works, so I read a book called, How things work. The book explained the physical principles and phenomenon of how various objects work, from light bulbs to nuclear bombs. In seventh grade, I read my sister’s physics book in high school during the summer to better understand natural phenomena. Then in high school, I read books on nutrition and learned about how the endocrine system and our health are affected by our food decisions.

To date, the medical scientist Seddighzadeh admires the most is the late Dr Jonas Salk. “I admire Dr. Salk’s ambition to use his training as a doctor and scientist to find a cure for polio and then help launch one of the most successful vaccination campaigns in history. Even more admirable was his decision not to patent the vaccine in order to make it accessible to the world. I am inspired by this intellect, this selflessness and this commitment to pursue medicine, and I hope to achieve it one day.

He plans to complete a residency in internal medicine in order to pursue a scholarship that will allow him to fulfill his dream of becoming a hematologist-oncologist. He said his father’s death from pancreatic cancer had a lot to do with his choice of medical specialty.

“I was called upon to become a doctor-researcher because, currently, we need better answers for many of our patients. For example, mesothelioma, pancreatic cancer and brain cancers all have five-year survival rates of less than 12%, ”Seddighzadeh said. “I want to use my clinical knowledge to treat my patients, their stories to inspire new laboratory research and the results of my research to help cure my patients more effectively. The future of medicine can only advance if we continue to take and shift the measure. “

Source link

]]> 0
NSW spearheads key COVID-19 vaccine research Fri, 04 Jun 2021 05:48:53 +0000

A leading group of experts in New South Wales will launch Australia’s first research to inform vaccine policy in the state and beyond.

The Collaborative Research Group on Vaccines, Infections and Immunology (VIIM) will receive more than $ 4.5 million in NSW government funding over three years to study clinical and immunological responses to COVID-19 vaccines in NSW beneficiaries.

VIIM brings together the leading researchers and practitioners in vaccines, infections and immunology in New South Wales. It integrates the expertise of two universities, four medical research institutes, the statewide pathology service, adult and pediatric health services and the National Center for Immunization Research and Surveillance.

NSW Director of Health Dr Kerry Chant said the program will strengthen our knowledge of COVID-19 vaccines, including their effectiveness against variant strains of the virus in the years to come.

“With the vaccine rollout now well underway, this real-world surveillance and research will continue to provide us with timely and robust data to ensure the best outcomes for the people of NSW and help us chart the way forward,” Dr Chant said. .

“This puts us in a strong position and will inform a vaccine policy that can address emerging issues and opportunities, as well as future development and testing of next-generation vaccines.

“We continue to learn throughout this pandemic and this research will allow us to advise on immunization schedules, including the potential need for booster vaccines for vulnerable groups and the wider community.”

Dr Chant said NSW is in a unique position to enrich the global body of knowledge on vaccines and immunity, as the majority of our population has not been exposed to COVID-19, unlike many other countries. .

“This research will also establish an invaluable biobank of specimens that will be crucial for current and future research to keep the people of NSW healthy and protected from infectious disease,” said Dr Chant.

VIIM’s experts in vaccines, infections and immunity are from the Western Sydney Local Health District, Sydney Local Health District, Sydney Children’s Hospital Network, NSW Health Pathology, National Center for Immunization Research and Surveillance, University of Sydney’s Marie Bashir Institute, University of NSW, Westmead Institute of Medical Research, Centenary Institute and Kirby Institute.

The grant is part of the $ 25 million COVID-19 priority research fund previously announced by the state.

/ Public distribution. This material is from the original organization and may be ad hoc in nature, edited for clarity, style and length. View full here.

Source link

]]> 0
New Zealand veterinary company ezyVet sold to foreign company Fri, 04 Jun 2021 02:53:59 +0000

Another New Zealand tech company has been taken over by a foreign buyer.

Photo: 123rf

Cloud-based veterinary company ezyVet has been sold to Nasdaq-listed pet company IDEXX Laboratories for an undisclosed amount.

The ezyVet product provides veterinarians and their clients with an online tool to monitor clinical records, manage schedules, calculate quotes and provide clinical summaries.

Founder and CEO Hadleigh Bognuda said the company looks forward to its future with IDEXX.

“We are delighted to combine our cutting-edge technology with IDEXX’s scale and commitment to innovation,” he said.

IDEXX Managing Director Jaz Mazelsky said he admired the way ezyVet made it possible for vets to focus more on their patients.

“EzyVet is a truly impressive cloud-native software solution that continues to transform the industry and the software experience for veterinarians.

Mazelsky said their growth has been very strong, but the real testament to what they have created is the satisfaction of their industry-leading customers.

The sale is the latest example of a local tech company that was acquired by a large offshore buyer this year, along with geoscience software developer Seequent, retail software company Vend, reservation technology company Timely and game developer Ninja Kiwi all sold for colossal sums.

In March, a market analyst said there was a lot of interest in New Zealand tech start-ups due to the high level of talent and entrepreneurial culture, and further acquisitions were expected.

Source link

]]> 0
Orthopedic Veterinary Implants Market Size (2021-2028) Thu, 03 Jun 2021 15:02:54 +0000

the Orthopedic Veterinary Implants Market The report includes a comprehensive analysis of all major aspects related to the market. All the important information about the market growth patterns and the growth factors responsible for them is covered in the research report. The market report also includes the detailed study of all the market restraints affecting the growth of the Veterinary Orthopedic Implants Market. The in-depth study of all the technological advancements in the Veterinary Orthopedic Implants industry is part of the Veterinary Orthopedic Implants market report. Relevant data on all product launches worldwide is covered in the research report. The research report covers comprehensive documentation of the market size at different times. The detailed analysis of the past statistics of the Veterinary Orthopedic Implants market is covered in the report along with the forecast for the future size of the Veterinary Orthopedic Implants during the forecast period.

Get | Download a sample copy with table of contents, graphics and list of figures @

The report covers the following key players in the Veterinary Orthopedic Implants Market:

• BioMedtrix
• Johnson & Johnson
• Veterinary orthopedic implants
• B. Braun Melsungen AG
• IMEX veterinarian

The Veterinary Orthopedic Implants market research report also offers insightful data on the major industry events taking place in the market over the years. These events include the main investments, collaborations, innovations, mergers made in this sector, etc. The report provides users with a detailed study of the growth pattern of Veterinary Orthopedic Implants industry. Further, the detailed analysis of all major growth drivers and market restraints is covered in the Market research report. The research report on the Orthopedic Veterinary Implants Market includes the study of all strategies involved in the growth process of the global market. Some of these strategies are data monitoring, passion, understanding potential customers, focus, communicating value to your customers, etc. To keep the growth of the global market at a steady rate, suppliers and manufacturers must follow these strategies.

Segmentation of the orthopedic veterinary implants market:

Orthopedic Veterinary Implants Market, By Product Type

• Veterinary plates and screws
• Joint replacement implants
o Hip replacement implants
o Knee replacement implants
o Others
• Others

Orthopedic Veterinary Implants Market, By End Users

• Veterinary hospitals
• Veterinary clinics
• Research institutes

The Veterinary Orthopedic Implants industry report provides a detailed analysis of the current market needs along with data to predict the future needs of the industry. The market report is considered as a comprehensive guide to deeply explore the Veterinary Orthopedic Implants industry. The research report is a comprehensive guide for understanding all the important aspects of the market for new entrants to the Veterinary Orthopedic Implants market. The research report on the Orthopedic Veterinary Implants market contains comprehensive documentation of the study of all segments of the market. The research report contains information on all the strategic developments that have been made in the Veterinary Orthopedic Implants industry over the years.

Get a discount on purchasing this report @

Scope of Orthopedic Veterinary Implants Market Report

Report attribute Details
Market size available for years 2021 – 2027
Reference year considered 2021
Historical data 2015 – 2019
Forecast period 2021 – 2027
Quantitative units Revenue in millions of USD and CAGR from 2021 to 2027
Covered segments Types, applications, end users, etc.
Cover of the report Revenue forecast, company ranking, competitive landscape, growth factors and trends
Regional scope North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Scope of customization Free customization of the report (equivalent to 8 working days for analysts) with purchase. Add or change the scope of country, region and segment.
Price and purchase options Take advantage of personalized shopping options to meet your exact research needs. Explore purchasing options

Geographical analysis of the orthopedic veterinary implants market:

– North America (United States, Canada, Mexico)
– Europe (Great Britain, France, Germany, Spain, Italy, Central and Eastern Europe, CIS)
– Asia Pacific (China, Japan, South Korea, ASEAN, India, rest of Asia-Pacific)
– Latin America (Brazil, rest of LA)
– Middle East and Africa (Turkey, CCG, rest of Middle East)

Visualize the Orthopedic Veterinary Implants Market Using Verified Market Intelligence: –

Verified Market Intelligence is our BI platform for narrative storytelling for this market. VMI offers in-depth forecasting trends and accurate insights into over 20,000 emerging and niche markets, helping you make critical revenue-impacting decisions for a bright future.

VMI provides a holistic overview and global competitive landscape with regard to region, country and segment as well as the major players in your market. Present your market report and findings with a built-in presentation function, saving over 70% of your time and resources for investor arguments, sales and marketing, R&D and product development. VMI enables data delivery in interactive Excel and PDF formats with over 15+ key market indicators for your market.

Visualize the Orthopedic Veterinary Implants Market Using VMI @

Why is the Veterinary Orthopedic Implants Market Report beneficial?

  • The Orthopedic Veterinary Implants report is compiled with in-depth and dynamic research methodology.
  • The report offers a complete picture of the competitive scenario of the Veterinary Orthopedic Implants market.
  • It includes a large amount of information on the latest technologies and product developments in the veterinary orthopedic implant industry.
  • The wide range of analyzes are associated with the impact of these improvements on the future growth of the Veterinary Orthopedic Implants industry.
  • The Orthopedic Veterinary Implants report combined the essential historical data and analysis required into a comprehensive research report.
  • The information in the Veterinary Orthopedic Implants report can be easily understood and contains a graphical representation of the numbers as bar charts, statistics and pie charts etc.

This in-depth study also includes a detailed description and interpretation of each chapter of the analysis. In order to give the users of this study a detailed overview of the Veterinary Orthopedic Implants industry, we have provided a comprehensive competitive landscape along with a product inventory of the most prominent vendors in various regions. Each chapter of the review is also defined and interpreted in detail in this systematic report. In order to provide users with this fact sheet and a detailed overview of the Veterinary Orthopedic Implants industry, we have created a broad competitive landscape along with a product summary of major vendors in various geographic economies.

For more information or a query or customization before purchasing, visit @

About Us: Verified Market Research ™

Verified Market Research ™ is a leading global research and consulting company providing advanced analytical research solutions, personalized advice and in-depth data analysis for over 10 years to individuals and businesses seeking precise research, reliable and up to date. technical data and advice. We provide insight into strategic and growth analytics, the data needed to meet business goals and help make critical revenue decisions.

Our research studies help our clients make better data-driven decisions, understand market forecasts, capitalize on future opportunities, and maximize efficiency by working as a partner to deliver accurate and valuable information. The industries we cover cover a broad spectrum including technology, chemicals, manufacturing, energy, food and beverage, automotive, robotics, packaging, construction, mining and manufacturing. gas. Etc.

At Verified Market Research, we help understand the holistic factors indicating the market and most current and future market trends. Our analysts, with their deep expertise in data collection and governance, use industry techniques to gather and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject matter expertise and years of collective experience to produce informative and accurate research.

After serving over 5,000 clients, we have provided reliable market research services to over 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the world’s largest consulting firms such as McKinsey & Company, Boston Consulting Group, Bain and Company for personalized research and consulting projects for businesses around the world.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research ™

United States: +1 (650) -781-480
UK: +44 (753) -715-0008
APAC: +61 (488) -85-9400
US Toll Free: +1 (800) -782-1768



Source link

]]> 0
Seattle Cancer Care Alliance (SCCA) clinicians’ clinical oncology results to be presented at ASCO’s annual meeting in 2021 Thu, 03 Jun 2021 11:00:00 +0000

SEATTLE – (COMMERCIAL THREAD) –Seattle Cancer Care Alliance (SCCA) today announced presentations from the organization’s clinicians to be presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting from June 4 to 8, 2021.

SCCA clinicians have contributed to studies of several types of cancer spanning the entire continuum of cancer care – from prevention to diagnosis to treatment. Presentations will highlight results from Phase 1 trials, CAR T therapy, breast cancer, bladder cancer, non-small cell lung cancer and hematologic cancers. In addition, there are numerous studies on the impact of the COVID-19 pandemic on cancer diagnosis, clinical care and clinical trials in oncology. SCCA clinical researchers have also contributed to new findings related to genetic profiling, prostate needle biopsy pathology, and precision therapy for salivary gland cancer.

“The SCCA is a leader in groundbreaking clinical trials turning scientific discoveries into exciting new treatments that often change the way cancer care is delivered,” said Nancy Davidson, MD, president and executive director of the Seattle Cancer Care Alliance and former president of ASCO. “The work presented by our physician-researchers at ASCO 2021 once again demonstrates these ongoing efforts to improve the way patients are treated and advance multidisciplinary cancer care. ”

More information on SCCA presentations and publications at ASCO is available at:

Presentation details:

Breast cancer screening in carriers of the pathogenic variants ATM, CHEK2 and PALB2: a comparative modeling analysis.

Abstract: 10500

Author of SCCA: Kathryn P. Lowry, MD

Impact of disruptions in breast cancer control due to the COVID-19 pandemic on breast cancer mortality in the United States: estimates from collaborative simulation modeling.

Abstract: 6562

Author of SCCA: Kathryn P. Lowry, MD

Adoptive immunotherapy phase I study for advanced MUC1 * positive breast cancer with autologous T cells designed to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1 *).

Abstract: TPS2663

Author of SCCA: Jennifer M. Specht, MD and David G. Maloney, MD, PhD

The efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR + / estrogen receptor (ER) + breast cancer in a clinical study international phase 2.

Abstract: 1020

Author of SCCA: Hannah M. Linden, MD

AMEERA-1: Phase 1/2 study of amenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER + / factor receptor Human epidermal growth 2-negative (HER2-) metastatic breast cancer (mBC).

Abstract: 1058

Author of SCCA: Hannah M. Linden, MD

Case-Based Panel: Optimizing Precision Therapy in Salivary Gland Cancers with a Look to the Future

SCCA speaker: Cristina P. Rodriguez, MD

PrE0807: A phase Ib feasibility study of neoadjuvant nivolumab (N) without or with lirilumab (L) in patients ineligible for cisplatin (pts) with muscular invasive bladder cancer (MCDI).

Abstract: 4518

Author of SCCA: Petros Grivas, MD, Ph.D.

Maintenance first-line (1L) Avelumab plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): analysis of time to end of next-line treatment in JAVELIN Bladder 100.

Abstract: 4525

Author of SCCA: Petros Grivas, MD, Ph.D.

Fluciclovine PET / CT (FACBC) in Oligometastatic Prostate Cancer (Flu-BLAST-PC).

Abstract: TPS5099

Author of SCCA: Risa L. Wong, Jonathan L. Wright, MD, MS, Heather H. Cheng, MD, PhD and Evan Y. Yu, MD

Clinical accuracy of information extracted from prostate biopsy pathology reports using natural language processing.

Abstract: 1557

Author of SCCA: Risa L. Wong and John L. Gore, MD, MS, FACS

Clinically advanced pelvic squamous cell carcinomas (pSCC) in men and women: a comprehensive genomic profiling study (CGP).

Abstract: 3130

Author of SCCA: Petros Grivas, MD, Ph.D.

Concordance of DNA damage repair (DDR) gene mutations in matched primary and metastatic prostate cancer (PC) samples.

Abstract: 5020

Author of SCCA: Michael T. Schweizer, MD, Evan Y. Yu, MD and Colin C. Pritchard, MD, PhD

Case-based panel: Optimizing the management of urothelial cancer from organ-confined disease to metastatic disease: a multidisciplinary approach

SCCA Moderator / President: Evan Y. Yu, MD

Oral session: Germline genetic testing for prostate cancer

Discussing the SCCA: Colin C. Pritchard, MD, PhD

The product type CD19 CAR T-cell has an independent impact on the severity of CRS and ICANS in patients with aggressive NHL.

Abstract: 7532

Author of SCCA: Jordan Gauthier, MD, M.Sc., Mazyar Shadman, MD, MPH, David G. Maloney, MD, PhD and Cameron J. Turtle, MBBS, PhD, FRACP, FRCPA

Efficacy of clinical breast examination in women surviving irradiated thorax from childhood Hodgkin lymphoma (HL).

Abstract: 10028

Author of SCCA: Janie M. Lee, MD, M.Sc.

Demographics, Outcomes, and Risk Factors for Patients (Pts) with Sarcoma and COVID-19: A Multi-Institutional Cohort Analysis.

Abstract: 11523

Author of SCCA: Michael J. Wagner, MD

Avelumab in patients with previously treated Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after more than five years of follow-up.

Abstract: 9517

Author of SCCA: Paul Nghiem, MD, PhD

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in non-small cell lung cancer (NSCLC) resistant to EGFR inhibitors and mutated to EGFR (EGFRm).

Abstract: 9007

Author of SCCA: Christina S. Baik, MD, MPH

Oral session: Emerging trends in radiation for localized lung cancers

SCCA speaker: Ramesh Rengan, MD, Ph.D.

Phase 1b dose escalation study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of GS-3583, an Fc agonist FLT3 fusion protein, in patients with advanced solid tumors.

Abstract: TPS3147

Author of SCCA: John A. Thompson, MD

First phase I / II human study of CYT-0851, a first-class inhibitor of homologous recombination mediated by RAD51 in patients with advanced solid and hematologic cancers.

Abstract: 3006

Author of SCCA: Ryan C. Lynch, MD

Training session: COG perspective on the impact of COVID-19 on pediatric oncology clinical trials and their implications for the future

SCCA speaker: Douglas S. Hawkins, MD

Discussion poster session: COVID-19 and cancer: learning as you go

SCCA speaker: Petros Grivas, MD, Ph.D.

Cancer Diagnosis and Adverse Financial Events: Evidence from Credit Reports.

Abstract: 6504

Author of SCCA: Veena Shankaran, MD, MS

Choosing Wisely: Selecting the Right Population at the Right Time for DNA Damaging Therapy

SCCA speaker: Elizabeth M. Swisher, MD

About Seattle Cancer Care Alliance

The Seattle Cancer Care Alliance brings together leading cancer research teams and specialists from Fred Hutch, Seattle Children’s and UW Medicine – an extraordinary group whose sole purpose is the pursuit of better, longer and richer lives for our patients. . Based in Seattle’s South Lake Union neighborhood, the Seattle Cancer Care Alliance has nine clinical care sites in the region, including a medical oncology clinic at EvergreenHealth in Kirkland; hematology / medical oncology and infusion services at Overlake Medical Center in Bellevue, medical and radiation oncology clinics at UW Medical Center – Northwest Seattle and medical oncology services at SCCA Issaquah, as well as network affiliations with hospitals in five states. For more information on SCCA, visit

Source link

]]> 0
Researchers are set to unravel the mystery of the science behind regeneration Thu, 03 Jun 2021 05:06:00 +0000

Many salamanders can easily regenerate a lost limb, but adult mammals, including humans, cannot. Why this is the case is a scientific mystery that has fascinated observers of the natural world for thousands of years.

Now, a team of scientists led by James Godwin, Ph.D., of the MDI Biological Laboratory in Bar Harbor, Maine, has come closer to this mystery with the discovery of differences in molecular signaling that promote regeneration in the axolotl , a highly regenerative salamander, while blocking it in the adult mouse, which is a mammal with limited regenerative capacity.

“Scientists at the MDI Biological Laboratory have relied on comparative biology to better understand human health since its founding in 1898,” said Hermann Haller, MD, president of the institution. “The discoveries made possible by James Godwin’s comparative studies on the axolotl and the mouse are proof that the idea of ​​learning from nature is as valid today as it was over 120 years ago. years.”

Instead of regenerating lost or injured body parts, mammals usually form a scar at the site of an injury. Because the scar creates a physical barrier to regeneration, regenerative medicine research at the MDI Biological Lab has focused on understanding why axolotl doesn’t form a scar – or why it doesn’t respond to injury the same way. than the mouse. and other mammals do.

Our research shows that humans have untapped potential for regeneration. If we can fix the problem of scar formation, maybe we can unleash our latent regenerative potential. Axolotls do not heal, which is what allows regeneration. But once a scar has formed, it’s over in terms of regeneration. If we could prevent scars in humans, we could improve the quality of life for so many people. “

James Godwin, PhD, MDI Biological Lab, Bar Harbor, Mount Desert Island Biological Lab

The axolotl as a model of regeneration

The axolotl, an almost extinct Mexican salamander in the wild, is a favorite model in regenerative medicine research because of its unique status as a champion of nature’s regeneration. While most salamanders have some regenerative capacity, axolotl can regenerate almost any part of the body, including the brain, heart, jaws, limbs, lungs, ovaries, spinal cord, skin, tail and more.

Since mammalian embryos and juveniles have the ability to regenerate – for example, human infants can regenerate heart tissue and children can regenerate fingertips – adult mammals are likely to retain the genetic code for regeneration, which suggests that pharmaceutical therapies could be developed to encourage humans to regenerate tissues and organs lost as a result of illness or injury instead of forming a scar.

In his recent research, Godwin compared immune cells called axolotl macrophages to those in mice in an attempt to identify the quality of axolotl macrophages that promote regeneration. The research builds on previous studies in which Godwin found that macrophages are essential for regeneration: When depleted, axolotl forms a scar instead of regenerating, just like mammals.

Recent research has found that although macrophage signaling in axolotl and in mice was similar when organisms were exposed to pathogens such as bacteria, fungi, and viruses, when it came to exposure to injury was a different story: signaling from macrophages in axolotl promoted new tissue growth while that in mice promoted healing.

The research article, titled “Distinct TLR Signaling in the Salamander Response to Tissue Damage” was recently published in the journal Developmental Dynamics. In addition to Godwin, the authors include Nadia Rosenthal, Ph.D., of the Jackson Laboratory; Ryan Dubuque and Katya E. Chan from the Australian Institute of Regenerative Medicine (ARMI); and Sergej Nowoshilow, Ph.D., Institute for Molecular Pathology in Vienna, Austria.

Godwin, who holds a joint appointment with The Jackson Laboratory, was previously associated with ARMI and Rosenthal is the founding director of ARMI. The MDI Biological Laboratory and ARMI have a partnership agreement to promote research and education on regeneration and the development of new therapies to improve human health.

Specifically, the article reported that the signaling response of a class of proteins called toll-type receptors (TLRs), which allow macrophages to recognize a threat such as infection or tissue damage and induce a pro response. -inflammatory, was “unexpectedly divergent” in response to injury in axolotl and mice. The discovery offers an intriguing window into the mechanisms governing regeneration in the axolotl.

To be able to “pull the levers of regeneration”

The discovery of an alternative signaling pathway compatible with regeneration could eventually lead to regenerative medicine therapies for humans. Although regrowth of a human limb may not be realistic in the short term, significant opportunities exist for therapies that improve clinical outcomes in diseases in which scarring plays a major role in pathology, including heart disease. , renal, hepatic and pulmonary.

“We are moving closer to understanding how axolotl macrophages are prepared for regeneration, which will bring us closer to the ability to pull the levers of regeneration in humans,” Godwin said. “For example, I imagine I could use a topical hydrogel at the wound site that is combined with a modulator that changes the behavior of human macrophages to look more like axolotl.”

Godwin, who is an immunologist, chose to examine the function of the immune system in regeneration because of its role in preparing the wound for repairs as the equivalent of a first responder at the site of an injury. . His recent research opens the door to further mapping of critical nodes in TLR signaling pathways that regulate the unique immune environment enabling axolotl regeneration and scar-free repair.


Journal reference:

Debuque, RJ, et al. (2021) Distinct toll receptor signaling in the salamander response to tissue damage. Development dynamics.

Source link

]]> 0
Veterinary hospitals have the option of keeping curbside appointments or making them in person Wed, 02 Jun 2021 21:48:00 +0000

It comes after New York State lifted the curbside warrant.

CHEEKTOWAGA, NY – The New York State border mandate for veterinary hospitals was lifted last week. This means pet owners can finally walk into the exam room instead of having to wait in their cars during appointments.

Before its lifting, only owners who had to euthanize their animals could go to hospitals.

New York State still requires masks, but leaves it up to vets to decide what other rules they wish to require.

Cheektowaga Veterinary Hospital is one such place that now allows pet owners to enter with their cats and dogs.

Although Dr Susan Wylegala said she was actually surprised at how less stressed animals didn’t have their owners inside before.

“I would say 95 percent a lot more relaxed without their owners in the building, a lot more relaxed,” Wylegala said. “Really, if an owner is nervous or expects their pet to be nervous then the animals would feed off that emotion for sure and without it for them it was a much more relaxing environment.”

Wylegala will also continue to offer curbside appointments even after the pandemic for this reason, and for the convenience of pet owners. Masks must be worn and a pet can only have one owner with them at this time.

However, Wylegala believes the curbside option is here to stay for the entire industry.

“As we move forward as a business, we always want to make it easier for our customers to get veterinary care,” she said.

While some pet owners have found the option more convenient under the tenure, Mariah Mekarski says it’s time for her to be up because her cat Tater Tot is getting too anxious without her at the Summer Cat Clinic. Buffalo Street.

“I am very happy because I take her at least twice a month for a blood sugar check and I always have to leave her at the front door and it is very sad,” Mekarski said.

Since the state has left it up to veterinary hospitals to decide whether they want pet owners to return indoors, it’s best to check with your pet’s doctor to see what they are.

Some have already put it on Facebook like Transit Animal Hospital and City Creatures Animal Hospital.

Source link

]]> 0
IDSA issues guidelines for SARS-CoV-2 antigen testing Wed, 02 Jun 2021 18:32:27 +0000 Subscribe We have not been able to …]]>

Hanson does not report any relevant financial disclosure.

We have not been able to process your request. Please try again later. If you continue to experience this problem, please contact

The Infectious Diseases Society of America has published new guidelines for the use of SARS-CoV-2 antigen tests.

“Antigen tests have really become more and more available during the pandemic and have helped us meet the need for more universal and faster access to diagnostic tests for SARS-CoV-2” Kimberly E. Hanson, MD, MHS, associate professor of internal medicine and assistant associate professor of pathology at the University of Utah School of Medicine, said at an IDSA news briefing. “These tests can be used in a variety of contexts. “

IDSA antigen test

Source: IDSA. IDSA diagnostic guidelines for COVID-19: antigen testing. Accessed June 2, 2021.

the advice was based on a systematic review of the literature by infectious disease clinicians and clinical microbiologists, which found that clinical performance data on rapid antigenic tests that have received emergency use clearance from the FDA are “primarily limited to a single point test compared to standard nucleic acid amplification test (NAAT) as a gold standard,” the guidelines panel wrote.

“Rapid antigenic tests have high specificity and low to modest sensitivity compared to standard NAAT methods. The sensitivity of the antigen test is highly dependent on viral load, with differences observed between symptomatic versus asymptomatic individuals and the time of testing after symptom onset, ”the panel wrote.

“Based on these observations, rapid RT-PCR or laboratory NAAT remain the diagnostic methods of choice for diagnosing SARS-CoV-2 infection,” the panel continued. “However, when molecular tests are not readily available or are logistically impractical, antigen testing can help identify some people infected with SARS-CoV-2.”

The guide, which was based on evidence categorized as “very low to moderate,” includes five diagnostic recommendations:

  • People with suspected symptoms of COVID-19 should be tested using NAAT (either rapid RT-PCR or laboratory NAAT) versus antigen testing.
  • Asymptomatic individuals at risk of exposure to SARS-CoV-2 should be tested via a single standard NAAT (either rapid RT-PCR or laboratory NAAT) versus a single rapid antigen test.
  • Asymptomatic individuals at risk of exposure to SARS-CoV-2 should receive a single standard NAAT (either rapid RT-PCR or laboratory NAAT) rather than two consecutive rapid antigen tests.
  • The panel does not recommend for or against rapid single antigen testing as opposed to not testing asymptomatic people at risk of exposure to SARS-CoV-2.
  • The IDSA does not advocate for or against the use of repeated rapid antigenic testing rather than not testing asymptomatic people at risk of exposure to SARS-CoV-2.

“When we reviewed the literature and made our recommendations and suggestions, this was a time when highly effective vaccines were not widely available and there was no significant coverage of the vaccinated adult population,” said Hanson . “It is likely that the role of testing will change as we see increased vaccine coverage in the population and the prevalence of infection in communities begins to decline – which we are already starting to see. “

The IDSA said the guidelines were approved by the American Society for Microbiology, the Society for Healthcare Epidemiology of America and the Pediatric Infectious Diseases Society.

Source link

]]> 0
Budget targets Removal of lead pipes, repairs to water supply infrastructure, job creation Wed, 02 Jun 2021 15:03:30 +0000

Every day, tens of millions of Americans drink primarily from lead straws. They get their drinking water from lead water pipes in the ground which can threaten their health by contributing to high levels of lead in their families’ tap water. Tens of millions more are served by decrepit water supplies struggling to provide water that meets basic health and safety standards. And when people in cities and towns across the country flush their toilets, sewage often goes untreated in rivers and lakes during storms due to insufficient sewers and water plants. treatment. Others have no sanitation at all, are left on “straight pipes” that bring their raw waste directly into a nearby stream, or still use backyard latrines.

Now is the time to invest in fixing our long overlooked hydraulic infrastructure defects that prompted the American Society of Civil Engineers to classify our drinking water systems to a “C-” and storm water systems to a “D.” It’s a newsletter that we would be ashamed to bring back to mom and dad.

The president’s budget for fiscal year 2022 (FY22) would be a down payment to deal with this crisis. It would invest $ 3.6 billion in hydraulic infrastructure. This would represent a modest but significant increase from the current fiscal year of roughly $ 2.8 billion invested in EPA water infrastructure funding.

Ultimately, it will take a lot more clearly. The US presidential plan for jobs would invest $ 45 billion to remove all lead pipes in the country from the ground, as well as significant additional investments in repairing our water infrastructure, for a total of $ 111 billion.

Investment in hydraulic infrastructure will be a big creator of jobs. For example, a recent study by the Metropolitan Planning Council found that replacing all of Illinois’ lead service lines alone could create up to 224,500 jobs and $ 23 billion in additional economic activity. Expand that to a national investment, and the number of new, well-paying jobs will be huge. Indeed, a University of Massachusetts study found that investing $ 35 billion per year in water infrastructure would create around 475,000 jobs. And most jobs in the water utility pay a good living wage; even at the lower end of the spectrum, a Brooking study found that jobs in the water industry pay up to 50 percent more than comparable jobs in other fields.

This investment will not only improve the protection of our water and create well-paying jobs, but it can and will address environmental injustices. The NRDC has learned from our partners in Flint, Newark, Pittsburgh and other cities, and from our reviews of EPA data, that those left behind by divestment in water infrastructure are communities of color to disproportionately low income. As shown in a study and map reproduced below developed by my colleague, Dr Kristi Pullen Fedinick, lead contamination is a national problem, but it is often more particularly concentrated in certain less wealthy communities.

Populations served by drinking water systems with 90th percentile lead samples greater than 1 part per billion

Kristi Pullen Fedinick (NRDC)

In addition to many urban communities that have suffered from severe disinvestment in their infrastructure, disadvantaged rural and tribal communities are also in serious danger. Families in these communities often have to live with severely contaminated water or no water at all on a daily basis, have lead service lines and sometimes have raw sewage flow in their streets or completely lack sanitation. In many of these communities, democracy itself has been seriously compromised. In Flint, for example, state-appointed officials made fateful reckless decisions that led to severe contamination, with residents and their elected officials effectively disenfranchised.

The time is long past for us to make the necessary investments to protect our health and our waterways. President Biden’s budget and the US Jobs Plan will take a big step towards making these essential investments.

Source link

]]> 0